3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
2
Pancreatic Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Melanoma
1
Locally Advanced Rectal Adenocarcinoma
1
Locally Advanced Cervical Carcinoma
1
Liver Neoplasms
1
Liver Diseases
1
Head and Neck Neoplasms
1
Gastric Cancer With Liver Metastases
1
Esophageal Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Oxaliplatin
3
Leucovorin
3
Fluorouracil
3
Capecitabine
3
zolbetuximab
2
trastuzumab deruxtecan
2
pembrolizumab
2
Ramucirumab
2
Paclitaxel
2
repotrectinib
1
lenvatinib
1
fludarabine
1
enzalutamide
1
durvalumab
1
darolutamide
1
aldesleukin
1
Vinorelbine
1
Radiosurgery
1
Radiation
1
Prednisone
1
Prednisolone
1
Positron-Emission Tomography
1
Pemetrexed
1
PF06821497
1
Nivolumab
1
Negative-Pressure Wound Therapy
1
Microscopy, Confocal
1
MORAb-202
1
Irinotecan
1
Immunotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Immunotherapy
×
30 days
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled